Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gundula Rendl, Gregor Schweighofer-Zwink, Stefan Sorko, Hans-Jürgen Gallowitsch, Wolfgang Hitzl, Diana Reisinger, Christian Pirich
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-04-01
Colecção:Cancers
Assuntos:
F-18 FDG PET/CT
radioiodine-refractory differentiated thyroid cancer
tyrosine kinase inhibitor
lenvatinib
metabolic response
Acesso em linha:https://www.mdpi.com/2072-6694/14/8/1868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados